Thymosin Beta-4 vs Dermorphin
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairAnti-Aging & Longevity
Thymosin Beta-4Recovery & Repair
Dermorphin- Summary
- Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Half-Life
- Not well characterized; likely similar to TB-500 (~1–2 hours)
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Admin Route
- SubQ, IM
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- Research
- —
- —
- Typical Dose
- 5–10 mg
- Not established for human use; research doses vary widely
- Frequency
- 2x per week (loading), then 1x per week (maintenance)
- Not established
- Key Benefits
- Systemic tissue repair and regeneration
- Promotes cardiac recovery after myocardial infarction
- Hair follicle regeneration and anti-hair-loss
- Anti-inflammatory (systemic)
- Wound healing acceleration
- Neuroprotection after brain injury
- Protects against ischemia-reperfusion injury
- Anti-aging at cellular level
- Synergizes powerfully with BPC-157
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Side Effects
- Generally very well tolerated
- Injection site reactions
- Mild fatigue at initiation (repair signaling)
- Rare: mild inflammatory response
- +1 more
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Stacks With
- —
- —